MICHAEL TAYLOR to Gene Regulatory Networks
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Gene Regulatory Networks.
Connection Strength
0.649
-
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018 01 04; 553(7686):101-105.
Score: 0.116
-
Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):E4325-34.
Score: 0.087
-
The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 2012 Nov; 181(5):1762-72.
Score: 0.081
-
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr; 123(4):615-26.
Score: 0.076
-
Gene context drift identifies drug targets to mitigate cancer treatment resistance. Cancer Cell. 2025 Sep 08; 43(9):1608-1621.e9.
Score: 0.049
-
Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. Genome Med. 2021 06 21; 13(1):103.
Score: 0.037
-
The transcriptional landscape of Shh medulloblastoma. Nat Commun. 2021 03 19; 12(1):1749.
Score: 0.036
-
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. 2019 09 16; 36(3):302-318.e7.
Score: 0.033
-
A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell. 2019 07 08; 36(1):51-67.e7.
Score: 0.032
-
A functional genomics approach to identify pathways of drug resistance in medulloblastoma. Acta Neuropathol Commun. 2018 12 27; 6(1):146.
Score: 0.031
-
Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-?-OTX2-SNAIL via PTEN inhibition. Brain. 2018 05 01; 141(5):1300-1319.
Score: 0.030
-
Canonical TGF-? pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. Brain Pathol. 2013 Mar; 23(2):178-91.
Score: 0.020
-
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):515-27.
Score: 0.019